GGrantIndex
← Search

NIDDM PRIMARY PREVENTION TRIAL

$35,553M01FY2000RRNIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications & trials

Abstract

Cellcept or Mycophenolate is an immunosuppresive drug which blocks the phosphoralation of inositol to convert it to guanidine. Already used in renal and liver transplants in adults, this study will evaluate the safety and efficacy of the drug in children who will undergo renal transplant. The primary efficacy endpoint is the proportion of patients with a rejection episode in the first 6 months.

View original record on NIH RePORTER →